BioLASCO Taiwan Co., Ltd. (6662) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of BioLASCO Taiwan Co., Ltd. stock TWD 22.94, price TWD 28.40, that is 19.2% below the price, quality 65 out of 100. Rating: overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.
How to read this chart
60‑month range 22.70 TWD – 35.18 TWD · fair‑value band 15.20 TWD – 32.05 TWD · the 28.40 TWD price screens above the 22.94 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.
Follow BioLASCO Taiwan Co. in your weekly email
Every Wednesday you see whether BioLASCO Taiwan Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
BioLASCO Taiwan Co., Ltd. operates an animal breeding center to produce specific pathogen-free laboratory animals in Taiwan and internationally.
Show moreShow less
The company offers lab animals, such as rat, mice, and others, as well as surgical services; and rodents housing, washing solutions, workstations, animal housing and management solutions, lab animal research equipment, clean solution, preclinical imaging system, and experimental equipment.
It also offers reagents, including lab animal diagnostic reagent, endotoxin testing system, portable endotoxin testing system, rapid microbial detection, biological indicators, and iReal antibody; and various services, such as animal testing, pathology and toxicology, serological testing, lab animal center management services.
BioLASCO Taiwan Co., Ltd. was founded in 1990 and is based in Taipei, Taiwan.
Stock analysis
BioLASCO Taiwan Co., Ltd. (6662) currently trades at 28.40 TWD, while our model-based Fair Value estimate is 22.94 TWD, 19% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 31.26 TWD per share, and 5 of the 24 models we run sit above the 28.40 TWD price.
Bear case: the Asset-Based group reads lowest at 2.98 TWD, and 19 of the 24 models stay below the price. Data coverage for this calculation is low.
Scenario range: 15.20 TWD (bear) to 32.05 TWD (bull), the price of 28.40 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 65/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
BioLASCO Taiwan Co., Ltd. reported revenue of 263M TWD in FY2025 versus 228M TWD in FY2021, a compound +3.6%/yr. Reported net income was 42.4M TWD in FY2025, compounding −1.5%/yr from FY2021.
Key figures
Market cap 727M TWD (≈ $22.2M) Micro · P/E ratio 17.9 · P/S ratio 2.82 · EPS (TTM) 1.59 TWD · Dividend yield 5.3% · Net margin 15.9% · Return on equity 9.6% · Return on assets (EBIT) 8.8% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 57 out of 100 (low confidence).
What moves the price
The share trades about 7% below its 52-week high and 5% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −19%, 6662 screens richer than that median.
Fair Value models
Bear15.20 TWDFair Value 22.94 TWDBull32.05 TWD
Price 28.40 TWD · Downside -19.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (1.36 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.64/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−10.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.6%
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+4.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year−1.2%
Dividend (yield on the price)5.3%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.24% → 18%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+13.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +11.5% a year for the price.
Compare BioLASCO Taiwan Co., Ltd. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 12/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score65 · Top 25%
Fair Value upside−19.2% · Above median
Profitability
Return on equity (12 months)9.6% · Top 25%
Return on assets7.2% · Top 25%
Net margin (12 months)15.9% · Above median
Operating margin (12 months)17.6% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)−8.2% · Below median
Dividend yield (12 months)5.3% · Top 25%
Balance sheet
Debt / equity0.17× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/E (12 months)17.9× · Cheaper than median
P/B1.59× · Cheaper than median
P/S (12 months)2.82× · Cheaper than median
Price / free cash flow (fiscal year)26.9× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is BioLASCO Taiwan Co., Ltd. (6662) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of 22.94 TWD versus a price of 28.40 TWD, about 19% lower (overvalued).
What is the fair value of 6662?
Our model-based fair value for BioLASCO Taiwan Co., Ltd. is 22.94 TWD (as of Nov 3, 2026), built from audited fundamentals. The current price: 28.40 TWD.
What is the quality score of 6662?
BioLASCO Taiwan Co., Ltd. has a Quality Score of 65/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BioLASCO Taiwan Co., Ltd. (6662)?
Our model-based price target is the fair value of 22.94 TWD (as of Nov 3, 2026) from 24 valuation models. Cautious scenario 15.20 TWD, optimistic scenario 32.05 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the BioLASCO Taiwan Co., Ltd. stock forecast for 2026?
Our models put fair value at 22.94 TWD, about 19% lower versus a price of 28.40 TWD (overvalued). Cautious scenario 15.20 TWD, optimistic scenario 32.05 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of BioLASCO Taiwan Co., Ltd. (6662)?
BioLASCO Taiwan Co., Ltd. reported trailing-twelve-month revenue of about 258M TWD (latest available figure, as of Nov 3, 2026).
Does BioLASCO Taiwan Co., Ltd. pay a dividend?
BioLASCO Taiwan Co., Ltd. currently shows a dividend yield of 5.29% relative to its recent price (as of Nov 3, 2026).
How much is the dividend of BioLASCO Taiwan Co., Ltd. (6662)?
BioLASCO Taiwan Co., Ltd. has a dividend yield of 5.3%.
What growth is priced into BioLASCO Taiwan Co., Ltd. (6662)?
For today's price to be fair in a discounted-cash-flow model, BioLASCO Taiwan Co., Ltd. would have to grow free cash flow by +13.3 % per year for five years (discount rate 9.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +3.7 % per year. As of Nov 3, 2026.
What discount rate (WACC) does the fair value of 6662 use?
Our models discount BioLASCO Taiwan Co., Ltd. at 9.0 %: a base by market capitalisation (nano), damped by beta 0.17, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For BioLASCO Taiwan Co., Ltd. that is +13.3 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.0 %) and the same formula as our fair value.
How much growth has BioLASCO Taiwan Co., Ltd. (6662) delivered so far?
Over the past 4 years revenue at BioLASCO Taiwan Co., Ltd. grew +3.7 % a year. The price currently implies free-cash-flow growth of +13.3 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of BioLASCO Taiwan Co., Ltd. (6662) growing?
The median revenue growth in the sector is +1.7 % a year. That is the yardstick for the growth priced into BioLASCO Taiwan Co., Ltd. (+13.3 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of BioLASCO Taiwan Co., Ltd. (6662)?
The free-cash-flow yield on the price is 3.72 %: that much free cash flow BioLASCO Taiwan Co., Ltd. produces per unit of market value. When it exceeds the discount rate of our models (9.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of BioLASCO Taiwan Co., Ltd. (6662)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BioLASCO Taiwan Co., Ltd. it is 22.94 TWD per share (as of Nov 3, 2026), against a price of 28.40 TWD. It is the blended result of 24 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is BioLASCO Taiwan Co., Ltd. stock overvalued or undervalued in 2026?
As of Nov 3, 2026, 6662 trades above its calculated fair value: price 28.40 TWD, fair value 22.94 TWD, a gap of about −19% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6662?
No. The price is what the market pays today (28.40 TWD); the fair value is what the company's own numbers justify (22.94 TWD). For BioLASCO Taiwan Co., Ltd. the two are 5.46 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is BioLASCO Taiwan Co., Ltd. worth?
The market values BioLASCO Taiwan Co., Ltd. at about 727M TWD (market capitalisation, as of Nov 3, 2026). Per share that is 28.40 TWD; our models calculate a fair value of 22.94 TWD per share.
What do the bullish and bearish scenarios say about 6662?
Our models span a range for BioLASCO Taiwan Co., Ltd.: cautious scenario 15.20 TWD, base 22.94 TWD, optimistic 32.05 TWD per share (as of Nov 3, 2026, price 28.40 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 6662?
BioLASCO Taiwan Co., Ltd. trades at a price-to-earnings ratio of 17.9 (as of Nov 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 22.94 TWD is built from several models across several years. Median P/E at fiscal year-end, 5 fiscal years (2021 to 2025), reported earnings: 18.1. Other multiples: P/B 1.6, P/S 2.8, EV/EBITDA 12.3.
How solid is the balance sheet of BioLASCO Taiwan Co., Ltd. (6662)?
Balance-sheet figures for BioLASCO Taiwan Co., Ltd. (as of Nov 3, 2026): return on equity 9.6%, debt of 0.17 per unit of equity. They feed the Quality Score of 65/100, which measures business quality independently of the share price.
How far is 6662 from its 52-week high?
BioLASCO Taiwan Co., Ltd. trades at 28.40 TWD, about 7% below its 52-week high of 30.50 TWD and 5% above the low of 27.04 TWD (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 22.94 TWD is for.
Which stocks are comparable to BioLASCO Taiwan Co., Ltd.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BioLASCO Taiwan Co., Ltd. stock attractive at the current price?
The data as of Nov 3, 2026: price 28.40 TWD, calculated fair value 22.94 TWD (−19%), Quality Score 65/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6662 calculated?
We run BioLASCO Taiwan Co., Ltd. through 24 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 22.94 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. BioLASCO Taiwan Co., Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BioLASCO Taiwan Co., Ltd. (6662)?
The closing price on Nov 6, 2026 was 28.40 TWD. Our model-based fair value is 22.94 TWD, about 19% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BioLASCO Taiwan Co., Ltd. right now?
Solid but not exceptional quality (65/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (15.20 TWD to 32.05 TWD) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of BioLASCO Taiwan Co., Ltd.
How large is the market capitalisation of BioLASCO Taiwan Co., Ltd. (6662)?
The market capitalisation of BioLASCO Taiwan Co., Ltd. is 727M TWD (≈ $22.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BioLASCO Taiwan Co., Ltd. (6662)?
The price-to-sales ratio of BioLASCO Taiwan Co., Ltd. is 2.82 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of BioLASCO Taiwan Co., Ltd. (6662)?
Earnings per share at BioLASCO Taiwan Co., Ltd. are 1.59 TWD (price ÷ EPS = P/E 17.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of BioLASCO Taiwan Co., Ltd. (6662)?
The dividend yield of BioLASCO Taiwan Co., Ltd. is 5.3% (payout 94.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of BioLASCO Taiwan Co., Ltd. (6662)?
The net margin of BioLASCO Taiwan Co., Ltd. is 15.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of BioLASCO Taiwan Co., Ltd. (6662)?
The return on equity (ROE) of BioLASCO Taiwan Co., Ltd. is 9.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BioLASCO Taiwan Co., Ltd. (6662)?
On an EBIT basis the return on assets of BioLASCO Taiwan Co., Ltd. is 8.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BioLASCO Taiwan Co., Ltd. (6662)?
The operating margin of BioLASCO Taiwan Co., Ltd. is 17.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BioLASCO Taiwan Co., Ltd. (6662)?
Revenue at BioLASCO Taiwan Co., Ltd. is growing −8.2% versus a year earlier (3y avg +3.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at BioLASCO Taiwan Co., Ltd. (6662)?
Earnings per share at BioLASCO Taiwan Co., Ltd. are growing −18.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does BioLASCO Taiwan Co., Ltd. (6662) carry?
The net debt of BioLASCO Taiwan Co., Ltd. is 10.8M TWD (fiscal year 2025, ≈ 0.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch BioLASCO Taiwan Co., Ltd. in the live analysis
One click puts BioLASCO Taiwan Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 3, 2026